You are here

Amgen

Amgen rejigs Bay Area presence with deal for new R&D facility

Amgen rejigs Bay Area presence with deal for new R&D facility

Fierce Biotech

Flag link:

ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid

ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid

Fierce Biotech

bispecific antibodies

Multiple Myeloma

Flag link:

3 Biotechs Facing FDA Approvals by Year's End

3 Biotechs Facing FDA Approvals by Year's End

Motley Fool

Intra-Cellular Therapies

Flag link:

4 FDA Dates Biotech Investors Should Circle in December

4 FDA Dates Biotech Investors Should Circle in December

Motley Fool

anti-inflammatories

Bausch Health Companies

Intra-Cellular Therapies

Flag link:

Top 7 Companies in Biotech Beach by Revenue

Top 7 Companies in Biotech Beach by Revenue

BioSpace

Acadia Pharmaceuticals

Mirati Therapeutics

Flag link:

Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster

Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster

Fierce Pharma

rheumatoid arthritis

Flag link:

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Fierce Pharma

Flag link:

Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.

Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.

Motley Fool

Flag link:

If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences

If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences

Motley Fool

Coherus Biosciences

Flag link:

Hit by copycat meds, Amgen trims 172 more jobs, this time in operations, R&D and sales

Hit by copycat meds, Amgen trims 172 more jobs, this time in operations, R&D and sales

Fierce Pharma

Flag link:

Top 10 pharma settlements since 2018

Top 10 pharma settlements since 2018

Fierce Pharma

Reckitt Benckiser

Teva Pharmaceutical

Flag link:

AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients

AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients

Fierce Pharma

PCSK9 inhibitor

Flag link:

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Endpoints

Flag link:

Amgen to cut 149 staff in retreat from neuroscience R&D

Amgen to cut 149 staff in retreat from neuroscience R&D

Fierce Biotech

Flag link:

It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster

It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster

Endpoints

Flag link:

Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J

Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J

BioSpace

Flag link:

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Pharmaforum

Flag link:

As Amgen zeroes in on cancer, neuroscience pipeline under the ax

As Amgen zeroes in on cancer, neuroscience pipeline under the ax

Fierce Biotech

Flag link:

Under copycat attack, Amgen punches back with its own biosimilars

Under copycat attack, Amgen punches back with its own biosimilars

Fierce Pharma

Flag link:

Bay Area Life Sciences Professionals Weigh In on Their Ideal Employers

Bay Area Life Sciences Professionals Weigh In on Their Ideal Employers

BioSpace

Gilead Sciences

Flag link:

Pages